Header Logo

Connection

Tyler Varisco to Humans

Back to Details
This is a "connection" page, showing publications Tyler Varisco has written about Humans.
Tyler Varisco
Connection Strength
1.064
Humans
  1. Antidepressant adherence using group-based trajectory modeling among postpartum women with Texas Medicaid. J Manag Care Spec Pharm. 2025 Feb 01; 31(2):167-178.
    View in: PubMed
    Score: 0.093
  2. Assessing the relationship between curricular placement of law courses and multistate pharmacy jurisprudence examination pass rates. Curr Pharm Teach Learn. 2024 Dec; 16(12):102202.
    View in: PubMed
    Score: 0.091
  3. Why the increase? Examining the rise in prescription medication expenditures in the United States between 2011 and 2020. Res Social Adm Pharm. 2024 04; 20(4):432-442.
    View in: PubMed
    Score: 0.087
  4. Regional Variation in Opioid-Related Emergency Medical Services Transfers During the COVID-19 Pandemic: An Interrupted Time Series Analysis. Subst Use Addctn J. 2024 Jan; 45(1):74-80.
    View in: PubMed
    Score: 0.087
  5. Outpatient opioid prescribing by Alzheimer's diagnosis among older adults with pain in United States. BMC Geriatr. 2023 08 01; 23(1):465.
    View in: PubMed
    Score: 0.084
  6. Patients prefer free drug disposal options delivered by pharmacists at the point of care: Results of a decision tree analysis of a national factorial vignette panel survey. Int J Drug Policy. 2023 06; 116:104045.
    View in: PubMed
    Score: 0.083
  7. Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Int J Infect Dis. 2020 10; 99:373.
    View in: PubMed
    Score: 0.068
  8. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach. Int J Drug Policy. 2020 09; 83:102827.
    View in: PubMed
    Score: 0.068
  9. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder. J Subst Abuse Treat. 2020 10; 117:108073.
    View in: PubMed
    Score: 0.068
  10. Using the theory of planned behavior to investigate community pharmacists' beliefs regarding engaging patients about prescription drug misuse. Res Social Adm Pharm. 2019 08; 15(8):992-999.
    View in: PubMed
    Score: 0.060
  11. Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
    View in: PubMed
    Score: 0.023
  12. Association of Emotional Intelligence With Pharmacy Students' Leadership and Academic Performance. Am J Pharm Educ. 2024 Dec; 88(12):101335.
    View in: PubMed
    Score: 0.023
  13. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.023
  14. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
    View in: PubMed
    Score: 0.023
  15. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.023
  16. Characterising incident opioid use among incident users of prescription sedative hypnotics: A national cohort study. BMJ Open. 2024 05 30; 14(5):e082339.
    View in: PubMed
    Score: 0.022
  17. Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2024 05; 34(4):201-209.
    View in: PubMed
    Score: 0.022
  18. Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents. J Clin Psychopharmacol. 2024 Mar-Apr 01; 44(2):124-132.
    View in: PubMed
    Score: 0.022
  19. Productivity Loss Among Opioid and Benzodiazepine Users in the United States: A Medical Expenditure Panel Survey From 2010 to 2019. J Occup Environ Med. 2024 Mar 01; 66(3):226-233.
    View in: PubMed
    Score: 0.022
  20. Physician perspective on the implementation of risk mitigation strategies when prescribing opioid medications: a qualitative analysis. BMC Health Serv Res. 2023 Oct 31; 23(1):1185.
    View in: PubMed
    Score: 0.021
  21. Factors associated with the use of the prescription monitoring program by prescribers and pharmacists in Texas. Pharmacoepidemiol Drug Saf. 2021 04; 30(4):492-503.
    View in: PubMed
    Score: 0.018
  22. Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas. J Addict Med. 2020 12; 14(6):e372-e374.
    View in: PubMed
    Score: 0.017
  23. Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications. Res Social Adm Pharm. 2021 01; 17(1):2005-2008.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.